- Home
- KMDA vs ARVN Comparison
KMDA vs ARVN Comparison
Compare KMDA & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KMDA
- ARVN
- Stock Information
- Founded
- KMDA 1990
- ARVN 2015
- Country
- KMDA Israel
- ARVN United States
- Employees
- KMDA N/A
- ARVN N/A
- Industry
- KMDA Biotechnology: Pharmaceutical Preparations
- ARVN Biotechnology: Pharmaceutical Preparations
- Sector
- KMDA Health Care
- ARVN Health Care
- Exchange
- KMDA Nasdaq
- ARVN Nasdaq
- Market Cap
- KMDA 410.6M
- ARVN 456.2M
- IPO Year
- KMDA N/A
- ARVN 2018
- Fundamental
- Price
- KMDA $7.32
- ARVN $8.03
- Analyst Decision
- KMDA Strong Buy
- ARVN Buy
- Analyst Count
- KMDA 2
- ARVN 22
- Target Price
- KMDA $13.00
- ARVN $20.21
- AVG Volume (30 Days)
- KMDA 51.8K
- ARVN 1.6M
- Earning Date
- KMDA 08-13-2025
- ARVN 10-29-2025
- Dividend Yield
- KMDA 2.80%
- ARVN N/A
- EPS Growth
- KMDA 27.97
- ARVN N/A
- EPS
- KMDA 0.32
- ARVN N/A
- Revenue
- KMDA $169,517,000.00
- ARVN $372,800,000.00
- Revenue This Year
- KMDA $14.49
- ARVN $4.87
- Revenue Next Year
- KMDA $10.12
- ARVN N/A
- P/E Ratio
- KMDA $21.69
- ARVN N/A
- Revenue Growth
- KMDA 9.67
- ARVN 299.57
- 52 Week Low
- KMDA $5.17
- ARVN $5.90
- 52 Week High
- KMDA $9.16
- ARVN $29.61
- Technical
- Relative Strength Index (RSI)
- KMDA 54.83
- ARVN 60.38
- Support Level
- KMDA $6.90
- ARVN $7.47
- Resistance Level
- KMDA $7.43
- ARVN $8.20
- Average True Range (ATR)
- KMDA 0.19
- ARVN 0.34
- MACD
- KMDA 0.03
- ARVN 0.07
- Stochastic Oscillator
- KMDA 80.19
- ARVN 82.54
About KMDA Kamada Ltd.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.